Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RET V804M RET M918T |
Therapy | Everolimus + Vandetanib |
Indication/Tumor Type | medullary thyroid carcinoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET V804M RET M918T | medullary thyroid carcinoma | resistant | Everolimus + Vandetanib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with thyroid medullary carcinoma harboring RET M918T progressed on multiple therapies, including Nexavar (sorafenib), Caprelsa (vandetanib), Cometriq (cabozantinib), MGCD-516 (sitravatinib), and RXDX-105 (CEP-32496), and upon progression with the combination therapy, Caprelsa (vandetanib) and Afinitor (everolimus), cell-free DNA testing revealed RET M918T and acquisition of a secondary drug resistant mutation, RET V804M (PMID: 29912274; NCT03157128). | 29912274 |
PubMed Id | Reference Title | Details |
---|---|---|
(29912274) | Selective RET kinase inhibition for patients with RET-altered cancers. | Full reference... |